Drug Trial Radar · NCT07616791
A Phase I Study of INT-210 Capsules in Healthy Adult Subjects (INT-210-I101)
Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
86
Actual
Start
Sep 4, 2025
Primary completion
Jan 6, 2026
Study completion Jan 6, 2026
Sponsor
- Lead sponsor
- Innatus Therapeutics (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase Ⅰ, Single and Multiple Ascending Dose escalation, and Food-Effect Study of the Safety, Tolerability and Pharmacokinetics of INT-210 Capsules in Healthy Adult Voluteers. Primary Objectives: ● To assess the safety and tolerability of single and multiple oral dose of INT-210 capsules in healthy adult voluteers, Secondary Objectives: * To assess the pharmacokinetic(PK) profile of single and multiple oral doses of INT-210 capsules in healthy adult voluteers; * To assess the safety and tolerability of INT-210 capsulese administered under fasting and fed(high-fat-meal) conditions in healthy adult voluteers; * To assess the effect of food on the PK profile of a single oral dose of INT-210 capsules in healthy adult voluteers;
Conditions
- IBD (Inflammatory Bowel Disease)
Interventions
INT-210 CapsuleDrug
400 mg INT-210; Oral administration
INT-210 CapsuleDrug
Escalating doses of 50, 100, 200, 400, 600, 800 mg of INT-210; Single dose administration; Oral administration
INT-210 CapsuleDrug
Escalating doses of 200, 400, 600 mg of INT-210; BID; Oral administration
INT-210 PlaceboDrug
INT-210 Placebo BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of treatment-emergent adverse eventsTime frame: From Day 1 through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
- Treatment-emergent potentially clinically- significant abnormalities in safety laboratory parameters-hematologyTime frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
- Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: coagulationTime frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
- Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: serum chemistryTime frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
- Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: urinalysisTime frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
- Treatment-emergent potentially clinically significant abnormalities in electrocardiogram values: QTcF (milliseconds)Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
- Treatment-emergent potentially clinically significant abnormalities in vital signs: heart rate (beats per minute)Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
- Treatment-emergent potentially clinically significant abnormalities in vital signs: blood pressure (mmHg)Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
- Treatment-emergent potentially clinically significant abnormalities in vital signs: respiration rate (BPM)Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
- Treatment-emergent potentially clinically significant abnormalities in vital signs: hemoglobin saturation (%)Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
- Treatment-emergent potentially clinically significant abnormalities in vital signs: temperature (℃)Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Municipality - Beijing Municipality - No. 101, Luyuan East Road, Tongzhou District, Beijing
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.